カリフォルニア州における血液疾患の臨床試験
カリフォルニア州内の拠点で、血液疾患に関する16件の研究が参加者を募集しています。
カリフォルニア州内の都市
公式研究テキスト（英語）
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Ctr for Inherited Blood Disorders, Orange
被験者募集中第3相
12歳〜100歳 · 全性別 · 2026/09/28更新 · NCT06439082Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 1, Duarte
- Quetzal Site 7, Los Angeles
- Quetzal Site 5, Stanford
被験者募集中第3相
18歳〜71歳 · 全性別 · 2026/09/23更新 · NCT07504458A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
- University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06722235(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- City of Hope Comprehensive Cancer Center, Duarte
- UCLA Medical Center, Los Angeles
- Stanford Cancer Institute, Stanford
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT04996875A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
- University of Southern California, Los Angeles
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/11更新 · NCT07059000A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
- University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06948318A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- City of Hope, Duarte
- Stanford University, Palo Alto
- UCSF, San Francisco
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07075185A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Pacific Cancer Medical Center, Inc, Anaheim
- TOI Clinical Research, Cerritos
- Stanford School of Medicine-Cancer Clinical Trials Office, Palo Alto
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05254743ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Orthopaedic Institute for Children HTC, Los Angeles
- Childrens Hospital Los Angeles, Los Angeles
- UCSF Benioff Children's Hospital Oakland, Oakland
- 他5件
被験者募集中観察研究
全年齢 · 全性別 · 2026/08/17更新 · NCT04398628Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- UCLA Department of Medicine, Los Angeles
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/07更新 · NCT07216443A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Keck School of Medicine of USC, Los Angeles
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/04/30更新 · NCT04256317Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
- USC / Norris Comprehensive Cancer Center, Los Angeles
被験者募集中観察研究健康なボランティア歓迎
19歳以上 · 全性別 · 2026/04/02更新 · NCT03207854Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
- Lucile Packard Children's Hospital, Palo Alto
被験者募集中第1相
1 Month – 45 Years · 全性別 · 2026/01/08更新 · NCT04640987Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- Lucile Packard Children's Hospital, Palo Alto
被験者募集中
1 Month – 60 Years · 全性別 · 2025/05/29更新 · NCT04249830The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research
- LabPMM, San Diego
被験者募集中観察研究
18歳以上 · 全性別 · 2025/05/04更新 · NCT06222164Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
- UC Davis Health, Sacramento
被験者募集中第1相
18歳以上 · 全性別 · 2025/04/13更新 · NCT05423691ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。